174 related articles for article (PubMed ID: 27329820)
1. Integrated genetic and pharmacologic interrogation of rare cancers.
Hong AL; Tseng YY; Cowley GS; Jonas O; Cheah JH; Kynnap BD; Doshi MB; Oh C; Meyer SC; Church AJ; Gill S; Bielski CM; Keskula P; Imamovic A; Howell S; Kryukov GV; Clemons PA; Tsherniak A; Vazquez F; Crompton BD; Shamji AF; Rodriguez-Galindo C; Janeway KA; Roberts CW; Stegmaier K; van Hummelen P; Cima MJ; Langer RS; Garraway LA; Schreiber SL; Root DE; Hahn WC; Boehm JS
Nat Commun; 2016 Jun; 7():11987. PubMed ID: 27329820
[TBL] [Abstract][Full Text] [Related]
2. Selinexor (KPT-330) Induces Tumor Suppression through Nuclear Sequestration of IκB and Downregulation of Survivin.
Nair JS; Musi E; Schwartz GK
Clin Cancer Res; 2017 Aug; 23(15):4301-4311. PubMed ID: 28314790
[No Abstract] [Full Text] [Related]
3. Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin.
Mittal K; Cooper GW; Lee BP; Su Y; Skinner KT; Shim J; Jonus HC; Kim WJ; Doshi M; Almanza D; Kynnap BD; Christie AL; Yang X; Cowley GS; Leeper BA; Morton CL; Dwivedi B; Lawrence T; Rupji M; Keskula P; Meyer S; Clinton CM; Bhasin M; Crompton BD; Tseng YY; Boehm JS; Ligon KL; Root DE; Murphy AJ; Weinstock DM; Gokhale PC; Spangle JM; Rivera MN; Mullen EA; Stegmaier K; Goldsmith KC; Hahn WC; Hong AL
Commun Biol; 2024 Apr; 7(1):426. PubMed ID: 38589567
[TBL] [Abstract][Full Text] [Related]
4. Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma.
Nakayama R; Zhang YX; Czaplinski JT; Anatone AJ; Sicinska ET; Fletcher JA; Demetri GD; Wagner AJ
Oncotarget; 2016 Mar; 7(13):16581-92. PubMed ID: 26918731
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.
Chen Y; Camacho SC; Silvers TR; Razak AR; Gabrail NY; Gerecitano JF; Kalir E; Pereira E; Evans BR; Ramus SJ; Huang F; Priedigkeit N; Rodriguez E; Donovan M; Khan F; Kalir T; Sebra R; Uzilov A; Chen R; Sinha R; Halpert R; Billaud JN; Shacham S; McCauley D; Landesman Y; Rashal T; Kauffman M; Mirza MR; Mau-Sørensen M; Dottino P; Martignetti JA
Clin Cancer Res; 2017 Mar; 23(6):1552-1563. PubMed ID: 27649553
[No Abstract] [Full Text] [Related]
6. FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models.
Corno C; Stucchi S; De Cesare M; Carenini N; Stamatakos S; Ciusani E; Minoli L; Scanziani E; Argueta C; Landesman Y; Zaffaroni N; Gatti L; Perego P
Biochem Pharmacol; 2018 Jan; 147():93-103. PubMed ID: 29155058
[TBL] [Abstract][Full Text] [Related]
7. Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing.
Neggers JE; Vercruysse T; Jacquemyn M; Vanstreels E; Baloglu E; Shacham S; Crochiere M; Landesman Y; Daelemans D
Chem Biol; 2015 Jan; 22(1):107-16. PubMed ID: 25579209
[TBL] [Abstract][Full Text] [Related]
8. Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin.
Garg M; Kanojia D; Mayakonda A; Ganesan TS; Sadhanandhan B; Suresh S; S S; Nagare RP; Said JW; Doan NB; Ding LW; Baloglu E; Shacham S; Kauffman M; Koeffler HP
Sci Rep; 2017 Aug; 7(1):9749. PubMed ID: 28852098
[TBL] [Abstract][Full Text] [Related]
9. CRM1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1-Dependent IGF-1 Signaling.
Sun H; Lin DC; Cao Q; Guo X; Marijon H; Zhao Z; Gery S; Xu L; Yang H; Pang B; Lee VK; Lim HJ; Doan N; Said JW; Chu P; Mayakonda A; Thomas T; Forscher C; Baloglu E; Shacham S; Rajalingam R; Koeffler HP
Cancer Res; 2016 May; 76(9):2687-97. PubMed ID: 26956669
[TBL] [Abstract][Full Text] [Related]
10. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
11. Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.
Murakami T; Singh AS; Kiyuna T; Dry SM; Li Y; James AW; Igarashi K; Kawaguchi K; DeLong JC; Zhang Y; Hiroshima Y; Russell T; Eckardt MA; Yanagawa J; Federman N; Matsuyama R; Chishima T; Tanaka K; Bouvet M; Endo I; Eilber FC; Hoffman RM
Oncotarget; 2016 Jul; 7(30):47556-47564. PubMed ID: 27286459
[TBL] [Abstract][Full Text] [Related]
12. Renal medullary carcinomas depend upon
Hong AL; Tseng YY; Wala JA; Kim WJ; Kynnap BD; Doshi MB; Kugener G; Sandoval GJ; Howard TP; Li J; Yang X; Tillgren M; Ghandi M; Sayeed A; Deasy R; Ward A; McSteen B; Labella KM; Keskula P; Tracy A; Connor C; Clinton CM; Church AJ; Crompton BD; Janeway KA; Van Hare B; Sandak D; Gjoerup O; Bandopadhayay P; Clemons PA; Schreiber SL; Root DE; Gokhale PC; Chi SN; Mullen EA; Roberts CW; Kadoch C; Beroukhim R; Ligon KL; Boehm JS; Hahn WC
Elife; 2019 Mar; 8():. PubMed ID: 30860482
[TBL] [Abstract][Full Text] [Related]
13. CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers.
Vijayaraghavan S; Karakas C; Doostan I; Chen X; Bui T; Yi M; Raghavendra AS; Zhao Y; Bashour SI; Ibrahim NK; Karuturi M; Wang J; Winkler JD; Amaravadi RK; Hunt KK; Tripathy D; Keyomarsi K
Nat Commun; 2017 Jun; 8():15916. PubMed ID: 28653662
[TBL] [Abstract][Full Text] [Related]
14. The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.
Vercruysse T; De Bie J; Neggers JE; Jacquemyn M; Vanstreels E; Schmid-Burgk JL; Hornung V; Baloglu E; Landesman Y; Senapedis W; Shacham S; Dagklis A; Cools J; Daelemans D
Clin Cancer Res; 2017 May; 23(10):2528-2541. PubMed ID: 27780859
[No Abstract] [Full Text] [Related]
15. [Radiation response enhanced by inhibition of XPO1 in preclinical rectal cancer models].
von Fallois M; Depping R
Strahlenther Onkol; 2016 Dec; 192(12):961-962. PubMed ID: 27757501
[No Abstract] [Full Text] [Related]
16. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
Turner JG; Dawson JL; Grant S; Shain KH; Dalton WS; Dai Y; Meads M; Baz R; Kauffman M; Shacham S; Sullivan DM
J Hematol Oncol; 2016 Aug; 9(1):73. PubMed ID: 27557643
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway.
von Witzleben A; Goerttler LT; Marienfeld R; Barth H; Lechel A; Mellert K; Böhm M; Kornmann M; Mayer-Steinacker R; von Baer A; Schultheiss M; Flanagan AM; Möller P; Brüderlein S; Barth TF
Cancer Res; 2015 Sep; 75(18):3823-31. PubMed ID: 26183925
[TBL] [Abstract][Full Text] [Related]
18. Human Exportin-1 is a Target for Combined Therapy of HIV and AIDS Related Lymphoma.
Boons E; Vanstreels E; Jacquemyn M; Nogueira TC; Neggers JE; Vercruysse T; van den Oord J; Tamir S; Shacham S; Landesman Y; Snoeck R; Pannecouque C; Andrei G; Daelemans D
EBioMedicine; 2015 Sep; 2(9):1102-13. PubMed ID: 26501108
[TBL] [Abstract][Full Text] [Related]
19. A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.
Menu E; Garcia J; Huang X; Di Liberto M; Toogood PL; Chen I; Vanderkerken K; Chen-Kiang S
Cancer Res; 2008 Jul; 68(14):5519-23. PubMed ID: 18632601
[TBL] [Abstract][Full Text] [Related]
20. A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma.
Dela Cruz FS; Diolaiti D; Turk AT; Rainey AR; Ambesi-Impiombato A; Andrews SJ; Mansukhani MM; Nagy PL; Alvarez MJ; Califano A; Forouhar F; Modzelewski B; Mitchell CM; Yamashiro DJ; Marks LJ; Glade Bender JL; Kung AL
Genome Med; 2016 Oct; 8(1):116. PubMed ID: 27799065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
